Search

Anastasiia S Boiko,1,* Ivan V Pozhidaev,1,* Diana Z Paderina,1 Anna V Bocharova,2 Irina A Mednova,1 Olga Yu Fedorenko,1 Elena G Kornetova,3,4 Anton JM Loonen,5 Arkadiy V Semke,3 Nikolay A Bokhan,6,7 Svetlana A Ivanova1,7 1Molecular Genetics and Biochemistry Laboratory, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; 2Laboratory of Evolutionary Genetics, Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; 3Endogenous Disorders Department, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; 4University Hospital, Siberian State Medical University, Tomsk, Russian Federation; 5Unit of Pharmacotherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands; 6Addictive Disorders Department, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; 7Psychiatry, Addiction Psychiatry and Psychotherapy Department, Siberian State Medical University, Tomsk, Russian Federation*These authors contributed equally to this workCorrespondence: Anton JM LoonenUnit of Pharmacotherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713AV, the NetherlandsTel +31 50 363 7576Email a.j.m.loonen@rug.nlPurpose: Metabolic syndrome (MetS) is characterized by abdominal obesity, hyperglycaemia, dyslipidaemia and hypertension. FTO gene has been implicated in the pathogenesis of obesity, but the available scientific data concerning their relationship to antipsychotic drug-induced obesity and metabolic syndrome is still incomplete and inconsistent, which indicates that continuing the investig